Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: sam who wrote (3182)	12/7/1997 7:16:00 AM
From: Andreas Helke	Read Replies (2) \| Respond to of 6136

I think it this is pretty much business as usual. The chemical departments of the pharmas have huge libraries of compounds wich might be useful as medicaments. The difficult part is then to figure out wich of these compounds to use for what indication. When Agouron searched a PI inhibitor they then screened the Eli Lilly library and since they found a suitable candidate it was of course a compound that was invented by Eli Lillys chemists. It was then just luck for Agouron that Eli Lilly later lost interest in the collaboration. Andreas

To: sam who wrote (3182)	12/7/1997 10:23:00 AM
From: Peter Singleton	Read Replies (1) \| Respond to of 6136

Sam, Great post on LLY and AGPH with respect to Viracept. From what I can gather, AGPH initiated their HIV program in 1987. They developed two novel classes of compounds that were highly potent in inhibiting the HIV protease enzyme. One of these classes was wholly owned by AGPH, one was developed under their collaboration with LLY. Apparently AG1343 (Viracept) came out of the class of compounds that was under their collaboration with LLY. In any event, AGPH's expertise in structure-based design, both in analyzing the molecular structure of the HIV protease target, and in optimizing the compounds which bound to that target, was of course essential to the design and development of 1343. The initial compound in the class that lead to Viracept appears to have come from a LLY compound library, but AG1343 is undoubtedly 1000s of times more potent (probably many 1000s of times), as a result of the structure-based design work of AGPH scientists. And, as you mentioned, since it was a collaborative effort, LLY scientists participated in the design work as well. So, to say Viracept was a compound found in a LLY compound library and hence not a tribute to AGPH's drug discovery/design expertise is inaccurate. Peter